Last reviewed · How we verify
All participants (Aviane)
Aviane is an oral contraceptive that prevents pregnancy by suppressing ovulation through a combination of ethinyl estradiol and levonorgestrel.
Aviane is an oral contraceptive that prevents pregnancy by suppressing ovulation through a combination of ethinyl estradiol and levonorgestrel. Used for Contraception (prevention of pregnancy).
At a glance
| Generic name | All participants (Aviane) |
|---|---|
| Also known as | Levonorgestrel and Ethinyl Estradiol |
| Sponsor | Oregon Health and Science University |
| Drug class | Oral contraceptive (combined estrogen-progestin) |
| Target | Progesterone receptor, estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Women's Health |
| Phase | FDA-approved |
Mechanism of action
Aviane contains a synthetic estrogen (ethinyl estradiol) and a progestin (levonorgestrel) that work together to inhibit the luteinizing hormone (LH) surge required for ovulation. The progestin component also thickens cervical mucus to impede sperm penetration and alters the endometrium to prevent implantation. This multi-mechanism approach provides contraceptive efficacy when taken daily.
Approved indications
- Contraception (prevention of pregnancy)
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
- A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (PHASE1)
- Validating and Assessing Reliability
- A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants (PHASE1)
- An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions (PHASE1)
- A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE) (PHASE1)
- Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics (PHASE4)
- Oral Contraceptives and Body Mass Index (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- All participants (Aviane) CI brief — competitive landscape report
- All participants (Aviane) updates RSS · CI watch RSS
- Oregon Health and Science University portfolio CI